Corrigendum to Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies (The Breast (2018) 41(S1) (S11–S12), (S0960977618301760), (10.1016/j.breast.2018.08.033))

Cristofanilli, Massimo; Harbeck, Nadia; Rugo, Hope S.; Castrellon, Aurelio; Joy, Anil Abraham; Verma, Sunil; Im, Seock-Ah; Iyer, Shrividya; Puyana Theall, Kathy; Gauthier, Eric; Huang, Xin; Bartlett, Cynthia Huang; Loibl, Sibylle; Finn, Richard S.

doi:10.1016/j.breast.2019.11.010

서울대학교 중앙도서관

S-Space 소개

My S-Space

로그인이 필요합니다.

S-Space

Publications

Detailed Information

Corrigendum to Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies (The Breast (2018) 41(S1) (S11–S12), (S0960977618301760), (10.1016/j.breast.2018.08.033)) : Efficacy + safety of palbociclib (P) in patients (pts) <= 50 y with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies (vol 41s1, pg s11, 2018)

Cited 0 time in Web of Science Cited 0 time in Scopus

Export

Authors: Cristofanilli, Massimo; Harbeck, Nadia; Rugo, Hope S.; Castrellon, Aurelio; Joy, Anil Abraham; Verma, Sunil; Im, Seock-Ah; Iyer, Shrividya; Puyana Theall, Kathy; Gauthier, Eric; Huang, Xin; Bartlett, Cynthia Huang; Loibl, Sibylle; Finn, Richard S.

Issue Date: 2020-02

Publisher: Churchill Livingstone

Citation: Breast, Vol.49, pp.131-131

Abstract: © 2019 Elsevier LtdTwo of the authors names appeared incorrectly in the byline. The correct names are Anil Abraham Joy and Kathy Puyana Theall.